A Comparative Study of Pharmacokinetics, Safety, and Immunogenicity of RPH-030 and Vectibix® in Patients With Metastatic Colorectal Cancer With Wild-type RAS as First-line Therapy in Combination With FOLFIRI

NCT07543744 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

180

Enrollment

INDUSTRY

Sponsor class

Conditions

Metastatic Colorectal Cancer

Interventions

DRUG: RPH-030
DRUG: Vectibix®
DRUG: Irinotecan
DRUG: Calcium Folinate
DRUG: Fluorouracil

Sponsor

R-Pharm